During the 2023 interim period, AIM-listed biotech company e-Therapeutics PLC continued to grow and advance its GalOmic RNAi therapeutics against target genes discovered using the group’s HepNet computational platform.
Through HepNet, e-therapeutics also generated positive proof-of-concept data for ETX-291 in cardiometabolic disease and ETX-148 in haemophilia.
The company also made strong progress in its immuno-oncology collaboration with iTeos Therapeutics, with continued delivery against pre-agreed milestones.
Post-period, the group appointed Timothy Bretherton as full-time chief finance officer, with Michael Bretherton stepping down from his interim role to resume as non-executive director.
Cash and cash equivalents at the end of the period were £24.8 million.
“Despite a severe macroeconomic climate, we have made significant progress during the past six months," said chief executive Ali Mortazavi.
“It is a tribute to our team that we have been able to translate our computational analyses into tangible assets, generating compelling preclinical data at a fraction of the R&D spend of any competitor.
“We look forward to showcasing additional data from our preclinical pipeline in the near future.”
Looking forward, e-therapeutics intends to adopt artificial intelligence (AI) into HepNet by implementing bespoke large-language models.
Mortazavi stated: “A year ago, generative AI technologies did not exist. Now, we are integrating them into every aspect of our drug development process, allowing us to develop our life-transforming RNAi medicines at pace.
“As we continue to leverage the most cutting-edge computation, I look forward to the future with confidence.”
e-therapeutics will continue to progress its therapeutic pipeline, with five assets currently in preclinical studies across a range of therapeutic areas, including cardiometabolic disease and haemophilia.